Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 28 04 2023
accepted: 06 06 2023
revised: 06 06 2023
medline: 21 9 2023
pubmed: 17 6 2023
entrez: 17 6 2023
Statut: ppublish

Résumé

The therapeutic advance in hereditary transthyretin amyloidosis (ATTRv amyloidosis) requires quantitative biomarkers of nerve involvement in order to foster early diagnosis and monitor therapy response. We aimed at quantitatively assessing Magnetic Resonance Neurography (MRN) and Diffusion Tensor Imaging (DTI) properties of the sciatic nerve in subjects with ATTRv-amyloidosis-polyneuropathy (ATTRv-PN) and pre-symptomatic carriers (ATTRv-C). Twenty subjects with pathogenic variants of the TTR gene (mean age 62.20 ± 12.04 years), 13 ATTRv-PN, and 7 ATTRv-C were evaluated and compared with 20 healthy subjects (mean age 60.1 ± 8.27 years). MRN and DTI sequences were performed at the right thigh from the gluteal region to the popliteal fossa. Cross-sectional-area (CSA), normalized signal intensity (NSI), and DTI metrics, including fractional anisotropy (FA), mean (MD), axial (AD), and radial diffusivity (RD) of the right sciatic nerve were measured. Increased CSA, NSI, RD, and reduced FA of sciatic nerve differentiated ATTRv-PN from ATTRv-C and healthy subjects at all levels (p < 0.01). NSI differentiated ATTRv-C from controls at all levels (p < 0.05), RD at proximal and mid-thigh (1.04 ± 0.1 vs 0.86 ± 0.11 p < 0.01), FA at mid-thigh (0.51 ± 0.02 vs 0.58 ± 0.04 p < 0.01). According to receiver operating characteristic (ROC) curve analysis, cutoff values differentiating ATTRv-C from controls (and therefore identifying subclinical sciatic involvement) were defined for FA, RD, and NSI. Significant correlations between MRI measures, clinical involvement and neurophysiology were found. In conclusion, the combination of quantitative MRN and DTI of the sciatic nerve can reliably differentiate ATTRv-PN, ATTRv-C, and healthy controls. More important, MRN and DTI were able to non-invasively identify early subclinical microstructural changes in pre-symptomatic carriers, thus representing a potential tool for early diagnosis and disease monitoring.

Identifiants

pubmed: 37329346
doi: 10.1007/s00415-023-11813-z
pii: 10.1007/s00415-023-11813-z
pmc: PMC10511361
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4827-4840

Informations de copyright

© 2023. The Author(s).

Références

Adams D, Koike H, Slama M, Coelho T (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol 15(7):387–404. https://doi.org/10.1038/s41582-019-0210-4
doi: 10.1038/s41582-019-0210-4 pubmed: 31209302
Coelho T et al (2018) Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology 91(21):e1999–e2009
doi: 10.1212/WNL.0000000000006543 pubmed: 30333157
Plante-Bordeneuve V (2018) Transthyretin familial amyloid polyneuropathy: an update. J Neurol 265(4):976–983. https://doi.org/10.1007/s00415-017-8708-4
doi: 10.1007/s00415-017-8708-4 pubmed: 29249054
Coelho T, Maurer MS, Suhr OB (2013) THAOS—the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 29(1):63–76. https://doi.org/10.1185/03007995.2012.754348
doi: 10.1185/03007995.2012.754348 pubmed: 23193944
Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D (2022) Hereditary transthyretin amyloidosis overview. Neurol Sci 43(2):595–604. https://doi.org/10.1007/s10072-020-04889-2
doi: 10.1007/s10072-020-04889-2 pubmed: 33188616
Adams D, Gonzalez-Duarte A, O’Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11–21. https://doi.org/10.1056/NEJMoa1716153
doi: 10.1056/NEJMoa1716153 pubmed: 29972753
Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22–31. https://doi.org/10.1056/NEJMoa1716793
doi: 10.1056/NEJMoa1716793 pubmed: 29972757
Coelho T, Maia LF, Martins da Silva A et al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79(8):785–792. https://doi.org/10.1212/WNL.0b013e3182661eb1
doi: 10.1212/WNL.0b013e3182661eb1 pubmed: 22843282 pmcid: 4098875
Kollmer J, Hegenbart U, Kimmich C et al (2020) Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis. Ann Clin Transl Neurol 7(5):799–807. https://doi.org/10.1002/acn3.51049
doi: 10.1002/acn3.51049 pubmed: 32333729 pmcid: 7261747
Kollmer J, Hund E, Hornung B et al (2015) In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain 138(Pt 3):549–562. https://doi.org/10.1093/brain/awu344
doi: 10.1093/brain/awu344 pubmed: 25526974
Kollmer J, Sahm F, Hegenbart U et al (2017) Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools. Neurology 89(5):475–484. https://doi.org/10.1212/WNL.0000000000004178
doi: 10.1212/WNL.0000000000004178 pubmed: 28679600
Hodel J, Benadjaoud S, Benadjaoud MA, Lefaucheur JP, Planté-Bordeneuve V (2022) 3-T MR neurography of lumbo-sacral plexus in hereditary transthyretin-related amyloidosis with polyneuropathy. Eur Radiol 32(11):7865–7871. https://doi.org/10.1007/s00330-022-08748-w
doi: 10.1007/s00330-022-08748-w pubmed: 35438324
Kollmer J, Bendszus M (2021) Magnetic resonance neurography: improved diagnosis of peripheral neuropathies. Neurotherapeutics 18(4):2368–2383
doi: 10.1007/s13311-021-01166-8 pubmed: 34859380 pmcid: 8804110
Breckwoldt MO, Stock C, Xia A et al (2015) Diffusion tensor imaging adds diagnostic accuracy in magnetic resonance neurography. Invest Radiol 50(8):498–504. https://doi.org/10.1097/RLI.0000000000000156
doi: 10.1097/RLI.0000000000000156 pubmed: 25850359
Heckel A, Weiler M, Xia A et al (2015) Peripheral nerve diffusion tensor imaging: assessment of axon and myelin sheath integrity. PLoS One. https://doi.org/10.1371/journal.pone.0130833
doi: 10.1371/journal.pone.0130833 pubmed: 26439494 pmcid: 4595131
Jeon T, Fung MM, Koch KM, Tan ET, Sneag DB (2018) Peripheral nerve diffusion tensor imaging: overview, pitfalls, and future directions. J Magn Reson Imaging 47(5):1171–1189. https://doi.org/10.1002/jmri.25876
doi: 10.1002/jmri.25876 pubmed: 29083521
Martin Noguerol T, Barousse R, Socolovsky M, Luna A (2017) Quantitative magnetic resonance (MR) neurography for evaluation of peripheral nerves and plexus injuries. Quant Imaging Med Surg 7(4):398–421. https://doi.org/10.21037/qims.2017.08.01
doi: 10.21037/qims.2017.08.01 pubmed: 28932698 pmcid: 5594015
Kronlage M, Schwehr V, Schwarz D et al (2018) Peripheral nerve diffusion tensor imaging (DTI): normal values and demographic determinants in a cohort of 60 healthy individuals. Eur Radiol 28(5):1801–1808. https://doi.org/10.1007/s00330-017-5134-z
doi: 10.1007/s00330-017-5134-z pubmed: 29230526
Gasparotti R, Lodoli G, Meoded A, Carletti F, Garozzo D, Ferraresi S (2013) Feasibility of diffusion tensor tractography of brachial plexus injuries at 1.5 T. Invest Radiol 48(2):104–112. https://doi.org/10.1097/RLI.0b013e3182775267
doi: 10.1097/RLI.0b013e3182775267 pubmed: 23249645
Gersing AS, Cervantes B, Knebel C et al (2020) Diffusion tensor imaging and tractography for preoperative assessment of benign peripheral nerve sheath tumors. Eur J Radiol 129:109110. https://doi.org/10.1016/j.ejrad.2020.109110
doi: 10.1016/j.ejrad.2020.109110 pubmed: 32559592
Haakma W, Hendrikse J, Uhrenholt L et al (2018) Multicenter reproducibility study of diffusion MRI and fiber tractography of the lumbosacral nerves. J Magn Reson Imaging 48(4):951–963. https://doi.org/10.1002/jmri.25964
doi: 10.1002/jmri.25964 pubmed: 29424083 pmcid: 6221026
Lemos N, Melo HJF, Sermer C et al (2021) Lumbosacral plexus MR tractography: a novel diagnostic tool for extraspinal sciatica and pudendal neuralgia? Magn Reson Imaging 83:107–113. https://doi.org/10.1016/j.mri.2021.08.003
doi: 10.1016/j.mri.2021.08.003 pubmed: 34400289
Liang KN, Feng PY, Feng XR, Cheng H (2019) Diffusion tensor imaging and fiber tractography reveal significant microstructural changes of cervical nerve roots in patients with cervical spondylotic radiculopathy. World Neurosurg 126:e57–e64. https://doi.org/10.1016/j.wneu.2019.01.154
doi: 10.1016/j.wneu.2019.01.154 pubmed: 30735862
Park SY, Koh SH, Lee IJ, Lee K, Lee Y (2021) Determination of optimum pixel size and slice thickness for tractography and ulnar nerve diffusion tensor imaging at the cubital tunnel using 3T MRI. Acta Radiol 62(8):1063–1071. https://doi.org/10.1177/0284185120951965
doi: 10.1177/0284185120951965 pubmed: 32854528
Wako Y, Nakamura J, Eguchi Y et al (2017) Diffusion tensor imaging and tractography of the sciatic and femoral nerves in healthy volunteers at 3T. J Orthop Surg Res 12(1):184. https://doi.org/10.1186/s13018-017-0690-0
doi: 10.1186/s13018-017-0690-0 pubmed: 29187253 pmcid: 5707804
Salvalaggio A, Coraci D, Cacciavillani M et al (2021) Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers. J Neurol 268(1):189–198. https://doi.org/10.1007/s00415-020-10127-8
doi: 10.1007/s00415-020-10127-8 pubmed: 32749600
Salvalaggio A, Coraci D, Cacciavillani M, Padua L, Briani C (2021) Nerve ultrasonography features in hereditary transthyretin amyloidosis with V30M mutation and polyneuropathy. Neurol Sci 42(6):2547–2548. https://doi.org/10.1007/s10072-020-05033-w
doi: 10.1007/s10072-020-05033-w pubmed: 33415458
Salvalaggio A, Coraci D, Obici L et al (2022) Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis. J Neurol 269(4):1905–1912. https://doi.org/10.1007/s00415-021-10754-9
doi: 10.1007/s00415-021-10754-9 pubmed: 34410494
Bril V (1999) NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol 41(Suppl 1):8–13. https://doi.org/10.1159/000052074
doi: 10.1159/000052074 pubmed: 10023123
England JD, Gronseth GS, Franklin G et al (2005) Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 64(2):199–207. https://doi.org/10.1212/01.WNL.0000149522.32823.EA
doi: 10.1212/01.WNL.0000149522.32823.EA pubmed: 15668414
Planté-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10(12):1086–1097. https://doi.org/10.1016/S1474-4422(11)70246-0
doi: 10.1016/S1474-4422(11)70246-0 pubmed: 22094129
Obici L, Mussinelli R (2021) Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future. Neurotherapeutics 18(4):2286–2302. https://doi.org/10.1007/s13311-021-01154-y
doi: 10.1007/s13311-021-01154-y pubmed: 34850359 pmcid: 8804119
Padua L, Coraci D, Lucchetta M et al (2018) Different nerve ultrasound patterns in charcot-marie-tooth types and hereditary neuropathy with liability to pressure palsies. Muscle Nerve 57(1):E18–E23. https://doi.org/10.1002/mus.25766
doi: 10.1002/mus.25766 pubmed: 28802056
Zaidman CM, Al-Lozi M, Pestronk A (2009) Peripheral nerve size in normals and patients with polyneuropathy: an ultrasound study. Muscle Nerve 40(6):960–966. https://doi.org/10.1002/mus.21431
doi: 10.1002/mus.21431 pubmed: 19697380
Hanyu N, Ikeda S, Nakadai A, Yanagisawa N, Powell HC (1989) Peripheral nerve pathological findings in familial amyloid polyneuropathy: a correlative study of proximal sciatic nerve and sural nerve lesions. Ann Neurol 25(4):340–350. https://doi.org/10.1002/ana.410250405
doi: 10.1002/ana.410250405 pubmed: 2540693
Kollmer J, Weiler M, Purrucker J et al (2018) MR neurography biomarkers to characterize peripheral neuropathy in AL amyloidosis. Neurology 91(7):e625–e634. https://doi.org/10.1212/WNL.0000000000006002
doi: 10.1212/WNL.0000000000006002 pubmed: 30030328
Vaeggemose M, Vaeth S, Pham M et al (2017) Magnetic resonance neurography and diffusion tensor imaging of the peripheral nerves in patients with Charcot-Marie-Tooth Type 1A. Muscle Nerve 56(6):E78–E84. https://doi.org/10.1002/mus.25691
doi: 10.1002/mus.25691 pubmed: 28500667
Vaeggemose M, Haakma W, Pham M et al (2020) Diffusion tensor imaging MR neurography detects polyneuropathy in type 2 diabetes. J Diabetes Complications 34(2):107439. https://doi.org/10.1016/j.jdiacomp.2019.107439
doi: 10.1016/j.jdiacomp.2019.107439 pubmed: 31672457
Kim HS, Yoon YC, Choi BO, Jin W, Cha JG, Kim JH (2019) Diffusion tensor imaging of the sciatic nerve in Charcot-Marie-Tooth disease type I patients: a prospective case-control study. Eur Radiol 29(6):3241–3252. https://doi.org/10.1007/s00330-018-5958-1
doi: 10.1007/s00330-018-5958-1 pubmed: 30635758
Xia X, Dai L, Zhou H et al (2021) Assessment of peripheral neuropathy in type 2 diabetes by diffusion tensor imaging: a case-control study. Eur J Radiol 145:110007. https://doi.org/10.1016/j.ejrad.2021.110007
doi: 10.1016/j.ejrad.2021.110007 pubmed: 34758418
Cortese A, Vegezzi E, Lozza A et al (2017) Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry 88(5):457–458. https://doi.org/10.1136/jnnp-2016-315262
doi: 10.1136/jnnp-2016-315262 pubmed: 28188196
Cheah PL, Krisnan T, Wong JHD et al (2021) Microstructural Integrity of peripheral nerves in charcot-marie-tooth disease: an MRI evaluation study. J Magn Reson Imaging 53(2):437–444. https://doi.org/10.1002/jmri.27354
doi: 10.1002/jmri.27354 pubmed: 32918328
Wang X, Luo L, Xing J et al (2022) Assessment of peripheral neuropathy in type 2 diabetes by diffusion tensor imaging. Quant Imaging Med Surg 12(1):395–405. https://doi.org/10.21037/qims-21-126
doi: 10.21037/qims-21-126 pubmed: 34993088 pmcid: 8666762
Wu C, Wang G, Zhao Y et al (2017) Assessment of tibial and common peroneal nerves in diabetic peripheral neuropathy by diffusion tensor imaging: a case control study. Eur Radiol 27(8):3523–3531. https://doi.org/10.1007/s00330-016-4698-3
doi: 10.1007/s00330-016-4698-3 pubmed: 28004159
Guggenberger R, Nanz D, Bussmann L et al (2013) Diffusion tensor imaging of the median nerve at 3.0 T using different MR scanners: agreement of FA and ADC measurements. Eur J Radiol 82(10):e590–e596. https://doi.org/10.1016/j.ejrad.2013.05.011
doi: 10.1016/j.ejrad.2013.05.011 pubmed: 23768611
Décard BF, Pham M, Grimm A (2018) Ultrasound and MRI of nerves for monitoring disease activity and treatment effects in chronic dysimmune neuropathies—current concepts and future directions. Clin Neurophysiol 129(1):155–167. https://doi.org/10.1016/j.clinph.2017.10.028
doi: 10.1016/j.clinph.2017.10.028 pubmed: 29190522
Sousa MM, Cardoso I, Fernandes R, Guimarães A, Saraiva MJ (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159(6):1993–2000. https://doi.org/10.1016/s0002-9440(10)63050-7
doi: 10.1016/s0002-9440(10)63050-7 pubmed: 11733349
Koike H, Ikeda S, Takahashi M et al (2016) Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology 87(21):2220–2229. https://doi.org/10.1212/WNL.0000000000003362
doi: 10.1212/WNL.0000000000003362 pubmed: 27794111
Sommer C, Schröder JM (1989) Amyloid neuropathy: immunocytochemical localization of intra- and extracellular immunoglobulin light chains. Acta Neuropathol 79(2):190–199. https://doi.org/10.1007/BF00294378
doi: 10.1007/BF00294378 pubmed: 2512758
Koike H, Katsuno M (2019) Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights. Biomedicines 7(1):11. https://doi.org/10.3390/biomedicines7010011
doi: 10.3390/biomedicines7010011 pubmed: 30764529 pmcid: 6466231
Conceição I, Damy T, Romero M et al (2019) Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid 26(1):3–9. https://doi.org/10.1080/13506129.2018.1556156
doi: 10.1080/13506129.2018.1556156 pubmed: 30793974
Grandis M, Obici L, Luigetti M et al (2020) Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. Orphanet J Rare Dis 15(1):348. https://doi.org/10.1186/s13023-020-01633-z
doi: 10.1186/s13023-020-01633-z pubmed: 33317601 pmcid: 7734774
Russo M, Obici L, Bartolomei I et al (2020) ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid 27(4):259–265. https://doi.org/10.1080/13506129.2020.1794807
doi: 10.1080/13506129.2020.1794807 pubmed: 32696671

Auteurs

Roberto Gasparotti (R)

Neuroradiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia and ASST Spedali Civili Hospital, P.Le Spedali Civili 1, 25123, Brescia, Italy. roberto.gasparotti@unibs.it.

Alessandro Salvalaggio (A)

Department of Neurosciences, University of Padova, Via Giustiniani 5, 35128, Padua, Italy.
Padova Neuroscience Center (PNC), University of Padova, Padua, Italy.

Daniele Corbo (D)

Neuroradiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia and ASST Spedali Civili Hospital, P.Le Spedali Civili 1, 25123, Brescia, Italy.

Giorgio Agazzi (G)

Neuroradiology Unit, ASST Santi Paolo e Carlo Hospital, Milan, Italy.

Mario Cacciavillani (M)

Data Medica Group, CEMES, Padua, Italy.

Alessandro Lozza (A)

Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Silvia Fenu (S)

Rare Neurological Diseases Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Grazia De Vigili (G)

Parkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Matteo Tagliapietra (M)

Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Gian Maria Fabrizi (GM)

Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Davide Pareyson (D)

Rare Neurological Diseases Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Laura Obici (L)

Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Chiara Briani (C)

Department of Neurosciences, University of Padova, Via Giustiniani 5, 35128, Padua, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH